Literature DB >> 15047520

Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals.

S Arunmozhi Balajee1, Molly Weaver, Alexander Imhof, Jennifer Gribskov, Kieren A Marr.   

Abstract

Isolates of Aspergillus fumigatus that demonstrate resistance to itraconazole (ITZ) have been described previously; however, the prevalence and clinical significance of ITZ resistance are not completely understood. In this study we assessed the ITZ susceptibilities of 128 A. fumigatus isolates that caused invasive infection in 82 stem cell transplant patients before and after the use of ITZ in our institution (study period, 1991 to 2000). The MICs for 10 isolates obtained from seven patients were high, > or 1 microg/ml. The average ITZ MIC increased after institutional use of the drug began in 1995. The majority of the isolates for which MICs were high (6 of 10) and one isolate for which the MIC was low (0.06 microg/ml) demonstrated an unusual phenotype, appearing as predominantly white colonies. For all seven atypical isolates, voriconazole MICs were high (> or = 2 microg/ml), and minimal effective concentrations of caspofungin were high (> or 4 microg/ml). For two of the seven atypical isolates, amphotericin B MICs were high (> or 2 microg/ml). The isolates appeared white due to slow sporulation; however, after prolonged incubations, the isolates sporulated with no difference in conidial color or conidiophore morphology compared with typical isolates. Randomly amplified polymorphic DNA-PCR patterns of these isolates were distinct compared with those of other A. fumigatus isolates. Sequencing of 18S rRNA genes confirmed that all were A. fumigatus; however, the mitochondrial cytochrome b gene sequences of all the atypical isolates were unique. These data suggest the potential presence of a genetically unique, poorly sporulating variant of A. fumigatus that demonstrates decreased susceptibilities to several antifungals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047520      PMCID: PMC375298          DOI: 10.1128/AAC.48.4.1197-1203.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  J.B. Georg W. Fresenius and the description of the species Aspergillus fumigatus in 1863.

Authors:  A Schmidt; D I Schmidt
Journal:  Contrib Microbiol       Date:  1999

2.  Mitochondrial cytochrome b gene analysis of Aspergillus fumigatus and related species.

Authors:  L Wang; K Yokoyama; M Miyaji; K Nishimura
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

3.  Identification of Aspergillus species using internal transcribed spacer regions 1 and 2.

Authors:  T Henry; P C Iwen; S H Hinrichs
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Molecular epidemiological study of Aspergillus fumigatus in a bone marrow transplantation unit by PCR amplification of ribosomal intergenic spacer sequences.

Authors:  S A Radford; E M Johnson; J P Leeming; M R Millar; J M Cornish; A B Foot; D W Warnock
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

5.  Neosartorya fischeri: an invasive fungal pathogen in an allogeneic bone marrow transplant patient.

Authors:  S Lonial; L Williams; G Carrum; M Ostrowski; P McCarthy
Journal:  Bone Marrow Transplant       Date:  1997-04       Impact factor: 5.483

6.  Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.

Authors:  D W Denning; S A Radford; K L Oakley; L Hall; E M Johnson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1997-09       Impact factor: 5.790

7.  Extreme DNA sequence variation in isolates of Aspergillus fumigatus.

Authors:  M E Katz; M Mcloon; S Burrows; B F Cheetham
Journal:  FEMS Immunol Med Microbiol       Date:  1998-04

8.  In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.

Authors:  P E Verweij; M Mensink; A J Rijs; J P Donnelly; J F Meis; D W Denning
Journal:  J Antimicrob Chemother       Date:  1998-09       Impact factor: 5.790

9.  In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

Authors:  C Lass-Flörl; G Kofler; G Kropshofer; J Hermans; A Kreczy; M P Dierich; D Niederwieser
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790

10.  Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR.

Authors:  K A Marr; C N Lyons; T R Rustad; R A Bowden; T C White; T Rustad
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more
  31 in total

1.  Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.

Authors:  Paul Bowyer; Juan Mosquera; Michael Anderson; Mike Birch; Michael Bromley; David W Denning
Journal:  FEMS Microbiol Lett       Date:  2012-05-21       Impact factor: 2.742

2.  Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation.

Authors:  J Guinea; T Peláez; L Alcalá; M J Ruiz-Serrano; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.

Authors:  Jesús Guinea; Sandra Recio; Teresa Peláez; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

4.  An alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains.

Authors:  L Alcazar-Fuoli; Mj Buitrago; A Gomez-Lopez; E Mellado
Journal:  Virulence       Date:  2015       Impact factor: 5.882

5.  Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Authors:  K Datta; P Rhee; E Byrnes; G Garcia-Effron; D S Perlin; J F Staab; K A Marr
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

6.  Role of Aspergillus lentulus 14-α sterol demethylase (Cyp51A) in azole drug susceptibility.

Authors:  Emilia Mellado; Laura Alcazar-Fuoli; Manuel Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

7.  Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient.

Authors:  Arlo Upton; Kieren A Marr
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

8.  Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus.

Authors:  S Arunmozhi Balajee; Jennifer L Gribskov; Edward Hanley; David Nickle; Kieren A Marr
Journal:  Eukaryot Cell       Date:  2005-03

9.  Aspergillus section Fumigati typing by PCR-restriction fragment polymorphism.

Authors:  Janet F Staab; S Arunmozhi Balajee; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

10.  Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.

Authors:  Laura Alcazar-Fuoli; Emilia Mellado; Ana Alastruey-Izquierdo; Manuel Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.